Nanotechnology-based drug delivery systems for dermatomycosis treatment

Current Nanoscience

Volumn 8, Issue 4, 2012, Pages 512-519

  de Souza, Ana Luiza Ribeiro ^a   Kiill, Charlene Priscila ^a   dos Santos, Fernanda Kolenyak ^a   da Luz, Gabriela Marielli ^a   Rocha e Silva, Hilris ^a   Chorilli, Marlus ^a   Gremião, Maria Palmira Daflon ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Dermatomycosis; Drug delivery systems; Nanotechnology

Indexed keywords

ALLYL AMINE; ANTI-FUNGAL; ANTIFUNGAL AGENTS; DERMATOMYCOSIS; DOSAGE FORMS; DRUG DELIVERY SYSTEM; FUNGAL INFECTION; HEALTH DISORDERS; MUCOUS MEMBRANES; NANOSTRUCTURED LIPID CARRIERS; NIOSOMES; RESIDENCE TIME; SIDE EFFECT; SILVER NANOPARTICLES; SOLID LIPID NANOPARTICLE (SLN); SPECIFIC DIAGNOSIS; STRATUM CORNEUM; SUSCEPTIBLE POPULATION; SYSTEMATIC REVIEW; TOPICAL DRUGS;

DRUG DOSAGE; DRUG INTERACTIONS; FUNGI; LIPOSOMES; LIQUID CRYSTALS; MICROEMULSIONS; NANOPARTICLES; NANOTECHNOLOGY; SILVER;

DRUG DELIVERY;

AMPHOTERICIN B; ANTIFUNGAL AGENT; CICLOPIROXOLAMINE; CLOTRIMAZOLE; ECONAZOLE; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; LIPOSOME; MICONAZOLE; MICONAZOLE NITRATE; NANOPARTICLE; NIOSOME; POLYGLACTIN; SILVER NANOPARTICLE; SOLID LIPID NANOPARTICLE; TERBINAFINE; WATER OIL CREAM;

DERMATOMYCOSIS; DERMATOPHYTOSIS; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG TRANSPORT; FIRST PASS EFFECT; FUNGICIDAL ACTIVITY; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; LIPOPHILICITY; LIQUID CRYSTAL; MICROEMULSION; NANOTECHNOLOGY; NONHUMAN; ONYCHOMYCOSIS; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; ROOM TEMPERATURE; SKIN PERMEABILITY; SURFACE CHARGE; TRANSMISSION ELECTRON MICROSCOPY; WOUND HEALING; X RAY CRYSTALLOGRAPHY;

EID: 84863925462     PISSN: 15734137     EISSN: 18756786     Source Type: Journal    
DOI: 10.2174/157341312801784311     Document Type: Review

References (121)

1. Cohn, M.S. Superficial fungal infections. Topical and oral treatment of common types. Postgrad. Med., 1992, 91, 239-244.
2. Somenzi, C.C.; Ribeiro, T.S.; Menezes, A. Características Particulares da Micologia Clínica o Diagnóstico Laboratorial de Micoses Superficiais. Rev. NewsLab, 2006, 77, 106-118.
3. Esteves, J.A.; Cabrita, J.D.; Nobre, G.N. Micologia médica, 2 ed.; Fundação Calouste Gulbenkian: Lisboa, 1990.
4. Lacaz, C.S., Porto, E., Martins, J.E.C., Heins-Accari, E.M., De Melo N.T. In: Tratado de micologia médica Lacaz, 9 ed.; Sarvier: São Paulo, 2002, pp. 252-340.
5. Sampaio, S. A. P., Rivitti, E. A. Dermatologia, 2 ed.; Artes Médicas, São Paulo, 2001, pp. 331-534.
6. Escutia, B., Feber, I., Pemán, J., Oliver, V., Sánchez-Corazo, J. L. Tinea capitis by Microsporum audouinii. Rev. Iberoam. Micol., 2001, 18, 88-90.
7. Patel, N.R. Itraconazole loaded poly(lactic-co-glycolic) acid nanoparticles for improved antifungal activity. Master Dissertation, Louisiana State University Louisiana: Louisiana, August 2010.
8. Jensen, R.; Mackey, D.R. In: Diseases of feedlot cattle. 2 ed.; Lea & Febiger: Philadelphia, 1974, pp. 377.
9. Rubio, M.C., Rezuta, A., Tomás, J., Ruesca, R.B. Mycological view of dermatrophytes in human. Rev. Iberoam. Micol. 1999, 16, 16-22.
10. Ayub, A.C.; Gomes, A.D.M.; Lima, M.V.C.; Vianna-Soares, C.D.; Ferreira, L.A.M. Topical delivery of fluconazole: in vitro skin penetration and permeation using emulsions as dosage forms. Drug Dev. Ind. Pharm., 2007, 33, 273-280.
11. Silva, C. L; Topgaard, D.; Kocherbitov, V.; Sousa, J. J. S.; Pais, A.A.C.C.; Sparr, E. Stratum corneum hydration: Phase transformations and mobility in stratum corneum, extracted lipids and isolated corneocytes. BBB-Biomembranes, 2007, 1768(11), 2647-2659.
12. Scheuplein, R.J.; Blank, I.H. Permeability of the skin. Physiol. Rev., 1971, 51, 702-747.
13. Tregear, R.T. The permeability of mammalian skin to ions. J. Invest. Dermatol., 1966, 46, 16-23.
14. Wallace, S.W.; Barnett, G. Pharmacokinetic analysis of percutaneous absorption: evidence of parallel penetration pathways for methotrexate. J. Pharmacokinet. Biop., 1978, 6, 315-325.
15. Goldsmith, L.A.; Baden, H.P. Uniquely oriented epidermal lipid. Nature, 1970, 225, 1052-1053.
16. Williams, A.C.; Barry, B.W. Skin absorption enhancers. Crit. Rev. Ther. Drug., 1992, 9, 305-353.
17. Stoughton, R.B. Percutaneous absorption of drugs. Ann. Rev. Pharmacol., 1989, 29, 55-69.
18. Baroli, B. Penetration of nanoparticles and nanomaterials in the skin: Fiction or Reality? J. Pharm. Sci., 2010, 99, 21-50.
19. Korting, M.S.; Mehnert, W.; Kortin, H.C. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv. Drug Deliv. Rev., 2007, 59, 427-443.
20. Pardeike, J.; Hommos, A.; Müller, R.H. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int. J. Pharm., 2009, 366, 170-184.
21. Kovacevic, A.; Savic, V.; Vuleta, G.; Müller, R.H.; Keck, C.M. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): Effects on size, physical stability and particle matrix structure. Int. J. Pharm., 2011, 406, 163-172.
22. Müller, R.H.; Radtke, M.; Wissing, S.A. Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm., 2002, 242, 121-128.
23. Smith, E.B. History of antifungals. J. Am. Acad. Dermatol., 1990, 23(4), 776-778.
24. Katz, H.I. Drug interactions of the newer oral antifungal agents. Br. J. Dermatol., 1999, 141, 26-32.
25. Hof, H. Developments in the epidemiolgy of invasive fungal infections-implications for the empiric and targeted antifungal therapy. Mycoses, 2008, 51, 1-6.
26. Zhang, A.Y.; Camp, W.L.; Boni, M.D.; Elewski, E. Advances in topical and systemic antifungals. Dermatol. Clin., 2007, 25, 165-183.
27. Georgopapadakou, N.H. Antifungals: mechanism of action and resistance, established and novel drugs. Curr. Opin. Microbiol., 1998, 1(5), 547-557.
28. Ryder, N.S.; Dupont, M.C. Inhibition of squalene epoxidase by allylamine antimycotic compounds: a comparative study of the fungal and mammalian enzymes. Biochem. J., 1985, 230(3), 765-770.
29. Roberts, D.T. Oral terbinafine (Lamisil) in the treatment of fungal infections of the skin and nails. Dermatology, 1997, 194 (1), 37-39.
30. Silveira, L.M.C., Ribeiro, V.M.B. Compliance with treatment groups: A teaching and learning grena for healthcare professionals, and patients. Interface, 2005, 9, 91-104.
31. Prow, T.W.; Grice, J.E.; Lin, L.L.; Faye, R.; Butler, M.; Becker, W.; Wurm, E.M.T.; Yoong, C.; Robertson, T.A.; Soyer, H.P.; Roberts, M.S. Nanoparticles and microparticles for skin delivery. Adv. Drug Deliv. Rev., 2011, 63, 470-491.
32. Küchler, S.; Herrmann, W.; Minkin, G.P.; Blaschke, T.; Zoscheke, C.; Kramer, K.D.; Bittl, R.; Korting, M.S. SLN for topical application in skin diseases-Characterization of drug-carrier and carrier-target interactions. Int. J. Pharm., 2010, 390, 225-233.
33. Mainardes, R.M.; Urban, M.C.C.; Cinto, P.O.; Chaud, M.V.; Evangelista, R.C.; Gremião, M.P.D. Lipossomes and micro/nanoparticles as colloidal for nasal drug delivery. Curr. Drug Deliv., 2006, 3(3), 275-285.
34. Berthold, A.; Cremer, K.; Kreuter, J. Collagen microparticles: carriers for glucocoticosteroids. Eur. J. Pharm. Biopharm., 1998, 45, 23-29.
35. Souto, E.B.; Wissing, S.A.; Barbosa, C.M.; Müller, R.H. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int. J. Pharm., 2004, 278, 71-77.
36. Zili, Z.; Sfar, S.; Fessi, H. Preparation and characterization of poly-caprolactone nanoparticles containing griseofulvin. Int. J. Pharm., 2005, 294, 261-267.
37. Saupe, A.; Gordon, K.C.; Rades, T. Structural investigations on nanoemulsions, solid lipid nanoparticles and nanostructured lipid carriers by cryofield emission scanning electron microscopy and Raman spectroscopy. Int. J. Pharm., 2006, 314, 56-62.
38. Silva, A.C.; Santos, D.; Ferreira, D.C.; Souto, E.B. Minoxidil-loaded nanostructured lipid carriers (NLC): characterization and rheological behaviour of topical formulation. Pharmazie, 2009, 64, 177-181.
39. Müller, R.H.; Radtke, M.; Wissing, S.A. Solid lipid nanoparticles and nanostructured lipid carriers. Encycl. Nanosci. Nanotechonol., 2004, 10, 43-56.
40. Joshi, M.D.; Müller, R.H. Lipid nanoparticles for parenteral delivery of actives. Eur. J. Pharm. Biopharm., 2009, 71, 161-172.
41. Yang, L.; Geng, Y.; Li, H.; Zhang, Y.; You, J.; Chang, Y. Enhancement the oral bioavailability of praziquantel by incorporation into solid lipid nanoparticles. Pharmazie, 2009, 64, 86-89.
42. Obeidat, W.M.; Schwabe, K.; Müller, R.H.; Keck, C.M. Preservation of nanostructured lipid carriers (NLC). Eur. J. Pharm. Biopharm., 2010, 76, 56-67.
43. Joshi, M.; Patravale, V. Nanostructured lipid carrier (NLC) based gel of celecoxib. Int. J. Pharm., 2008, 346, 124-132.
44. Karate, O.P.; Raza, K.; Singh, B.; Dogra, S. Novel drug delivery systems in topical treatment of psoriasis: Rigors and vigors. Ind. J. Dermatol. Venerol. Leprol., 2010, 76, 612-621.
45. Müller, R.H.; Möschwitzer, J.; Bushrab, F.N. Manufacturing of nanoparticles by milling and homogenization techniques. In: Nanoparticle technology for drug delivery. Taylor & Francis, 2006, vol. 159, pp. 21-51.
46. Bhalekar, M.R.; Pokharkar, V.; Madgulkar, A.; Patil, N.; Patil, N. Preparation and evaluation of miconazole nitrate-loaded solid lipid nanoparticles for topical delivery. AAPS Pharm. Sci., 2009, 10(1), 289-296.
47. Passerini, N.; Gavini, E.; Albertini, B.; Rassu, G.; Sabatino, M.D.; Sanna, V.; Giunchedi, P.; Rodriguez, L. Evaluation of solid lipid microparticles produced by spraycongealing for topical application of econazole nitrate. J. Pharm. Pharmacol., 2009, 61, 559-567.
48. Schabes-Retchkiman, P.S.; Canizal, G.; Herrera-Becerra, R.; Zorrilla, C.; Liu, H.B.; Ascencio, J.A. (2006). Biosynthesis and characterization of Ti/Ni bimetallic nanoparticles. Opt. Mater., 2006, 29(1), 95-99.
49. Gu, H.; Ho, P.L.; Tong, E.; Wang, L.; Xu, B. Presenting vancomycin on nanoparticles to enhance antimicrobial activities. Nano Lett., 2003, 3(9), 1261-1263.
50. Ahmad, Z.; Pandey, R.; Sharma, S.; Khuller, G.K. Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential. Ind. J. Chest. Dis. Allied. Sci., 2005, 48, 171-176.
51. Gong, P.; Li, H.; He, X.; Wang, K.; Hu, J.; Tan, W. Preparation and antibacterial activity of Fe3O4-Ag nanoparticles. Nanotechnology, 2007, 18, 604-611.
52. Klasen, H.J. A historical review of the use of silver in the treatment of burns. II. Renewed interest for silver. Burns, 2000, 26, 131-138.
53. Russell, A.D.; Hugo W.B. Antimicrobial activity and action of silver. Progr. Med. Chem., 1994, 31, 351-370.
54. Silver, S. Bacterial silver resistance: molecular biology and uses and misuses of silver compounds. FEMS. Microbiol. Rev., 2003, 27, 341-353.
55. Lok, C.N.; Ho, C.M.; Chen, R.; He, Q.Y.; Yu, W.Y.; Sun, H.; Tam, P.K.; Chiu, J.F.; Chen, C.M. Proteomic analysis of the mode of antibacterial action of silver nanoparticles. J. Proteome. Res., 2006, 5, 916-924.
56. Zhao, G.J.; Stevens, S.E. Multiple parameters for the comprehensive evaluation of the susceptibility of Escherichia coli to the silver ion. Biometals, 1998, 11, 27-32.
57. Franke, S.; Grass, G.; Nies, D.H. The product of the ybdE gene of the Escherichia coli chromosome is involved in detoxification of silver ions. Microbiology, 2001, 147, 965-972.
58. Tian, J.; Wong, K.K.; Ho, C.M.; Lok, C.N.; Yu, W.Y.; Che, C.M.; Chiu, J.F.; Tam, P.K. Topical delivery of silver nanoparticles promotes wound healing. Chem. Med. Chem., 2007, 2, 129-136.
59. Shahverdi, A.R.; Fakhimi A.; Shahverdi, H.R.; Minanian, S. Synthesis and effect of silver nanoparticles on the antibacterial activity of different antibiotics against S. aureus and E. coli. Nanomedicine, 2007, 3, 168-171.
60. Kim, J.S.; Kuk, E.; Yu, K.N.; Kim, J.H.; Park, S.J.; Lee, H.J. Antimicrobial effects of silver nanoparticles. Nanomedicine, 2007, 3, 95-101.
61. Kim, K.J.; Sung, W.S.; Moon, S.K.; Choi, J.S.; Kim, J.G.; Dong, G.L. Antifungal effect of silver nanoparticles on dermatophytes. J. Microbiol. Biotechnol., 2008, 18, 1482-1484.
62. Kim, K.J.; Sung, W.S.; Suh, B.K.; Moon, S.K.; Choi, J.S.; Kim, J.G. Antifungal activity and mode of action of silver nanoparticles on Candida albicans. Biometals, 2009, 22, 235-242.
63. Petica, A.; Gavriliu, S.; Lungua, M.; Burunteaa, N.; Panzarub, C. Colloidal silver solutions with antimicrobial properties. Mater. Sci. Eng., 2008, 152, 22-27.
64. Pal, S.; Tak, Y.K.; Song, J.M. Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the gramnegative bacterium Escherichia coli. Appl. Environ. Microb., 2007, 73, 1712-1720.
65. Noorbakhsh, F.; Rezaie, S.; Shahverdi, A.R. In: Antifungal Effects of Silver Nanoparticle alone and with Combination of Antifungal Drug on Dermatophyte Pathogen Trichophyton Rubrum of the International Conference on Bioscience, Biochemistry and Bioinformatics IPCBEE, 2011, 5, pp.364-367.
66. Alsarra, I.A.; Bosela, A.A.; Ahmed, S.M.; Mahrous, G.M. Proniosomes as a drug carrier for transdermal delivery of ketorolac. Eur. J. Pharm. Biopharm., 2005, 59, 485-490.
67. Bangham, A.D.; Standish, M.M.; Watkins, J.C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol., 1965, 13, 238-252.
68. Agarwal, R.; Katare, O.P.; Vyas, S.P. Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int. J. Pharm., 2001, 228, 43-52.
69. Honeywell-Nguyen, P.L.; Bouwstra, J.A. Vesicles as a tool for transdermal and dermal delivery. Drug Discov. Today, 2005, 2(1), 67-74.
70. Uchegbu, I.F.; Vyas, S.P. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int. J. Pharm., 1998, 172, 33-70.
71. Betageri, G.; Habib, M. Liposomes as drug carriers. Pharm. Eng., 1994, 14, 76-77.
72. El-Laithy, H.M.; Shoukry, O.; Mahran, L.G. Novel sugar esters proniosomes for trandermal delivery of vinpocetine: Preclinical and clinical studies. Eur. J. Pharm. Biopharm., 2011, 77, 43-55.
73. Shaikh, K.S.; Chellampillai, B.; Pawar, A.P. Studies on nonionic surfactant bilayer vesicles of cliclopirox olamine. Drug Dev. Ind. Pharm., 2010, 36(8), 946-953.
74. Verma, A.M.L.; Palani, S. Development and in vitro evaluation of liposomal gel of ciclopirox olamine. Int. J. Pharm. Bio Sci., 2010, 1(2), 1-6.
75. Girhepunje, K.; Pal, R.; Behera, A.; Husen, M.; Thirumoorthy, N. Transdermal delivery of ciclopirox olamine via liposomal carrier. J. Pharm. Res., 2010, 3(12), 2858-2900.
76. Agarwal, R.; Katare, O.P. Preparation and in vitro evaluation of miconazole nitrate-loaded topical liposomes. Pharm. Technol., 2002, 48-60.
77. Kassem, M.A.A.; Esmat, S.; Bendas, E.R.; El-Komy, M.H.M. Efficacy of topical griseofulvin in treatment of tinea corporis. Mycoses, 2006, 49, 232-235.
78. Touitou, E.; Dayan, N.; Bergelson, L.; Godin, B.; Eliaz, M. Ethosomes-novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J. Control. Release, 2000, 65, 403-418.
79. Honeywell-Nguyen, P.L.; Graaff, A.M.; Groenink, H.W.W.; Bouwstra, J.A. The in vivo and in vitro interactions of elastic and rigid vesicles with human skin. Biochim. Biophys. Acta, 2002, 1573, 130-140.
80. Cevc, G.; Blume, G. Lipid vesicles penetrate into the skin owing to the transdermal osmotic gradients and hydration force. Biochim. Biophys. Acta, 1992, 1104, 226-232.
81. Cevc, G.; Blume, G.; Schätzlein, A. Transfersomes-mediated transepidermal delivery improves the region-specificity and biological activity of corticosteroids in vivo. J. Control. Release, 1997, 45, 211-226.
82. Karande, P.; Mitragotri, S. Enhancement of transdermal drug delivery via synergistic action of chemicals. Biochim. Biophys. Acta, 2009, 1788, 2362-2373.
83. Qiu, Y.; Gao, Y.; Hu, K.; Li, F. Enhancement of skin permeation of docetaxel: A novel approach combining microneedle and elastic liposomes. J. Control. Release, 2008, 129, 144-150.
84. Ghannoum, M.; Isham, N.; Herbert, J.; Henry, W.; Yurdakul, S. Activity of TDT 067 (terbinafine in transfersome) against agents of onychomycosis, as determined by minimum inhibitory and fungicidal concentrations. J. Clin. Microbiol., 2011, 49(5), 1716-1720.
85. Kreilgaard, M. Influence of microemulsions on cutaneous drug delivery. Adv. Drug Deliv. Rev., 2002, 54, 77-98.
86. Kogan, A.; Garti, N. Microemulsions as transdermal drug delivery vehicles. Adv. Colloid Interfac., 2006, 123-126, 369-385.
87. Peira, E.; Carlotti, M.E.; Trotta, C.; Cavalli, R.; Trotta, M. Positively charged microemulsions for topical application. Int. J. Pharm., 2008, 346, 119-123.
88. Heuschkel, S.; Goebel, A.; Neubert. R.H.H. Microemulsions-Modern colloidal carrier for dermal and transdermal drug delivery. Int. J. Pharm. Sci., 2008, 97(2), 603-631.
89. Carvalho, F.C.; Mainardes, R.M.; Gremião, M.P.D. In: Exploring of the nanotechnology-based drug delivery systems for AIDS treatment. Aids 4: InTech; Vienna, 2011, pp. 150.
90. Chorilli, M.; Prestes, P.S.; Rigon, R.B.; Leonardi, G.R.; Chiavacci, L.A.; Sarmento, V.H.V.; Oliveira, A.G.; Scarpa, M.V. Structural characterization and in vivo evaluation of retinyl palmitate in non-ionic lamellar liquid crystalline system. Colloids Surfac. B: Biointerfaces, 2011, 85(2), 182-188, 2011.
91. Friberg, S.E.; Bothorel, P. In: Microemulsions: Structure and dynamics; CRC: New York, 1988; pp. 219.
92. Constantinides, P.P.; Scarlat, J.P.; Lancaster, C.; Marcello, J.; Marks, G.; Ellens, H.; Smith, P.L. Formulation and intestinal absorption enhancement evaluation of water in oil microemulsions incorporating medium-chain glycerides. Pharm. Res., 1994, 11, 1385-1390.
93. Constantinides, P.P. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm. Res., 1995, 12, 1561-1572.
94. Oliveira, A.G.; Scarpa, M.V.; Chaimovich, H. Effect of hexadecyltrimethylammonium bromide-based microemulsions on the rate of decomposition of the betalactam antibiotic cephaclor. J. Pharm. Sci., 1997, 86, 616-620.
95. Dalmora, M.E.; Oliveira, A.G. Inclusion complex of piroxicam withcyclodextrin and incorporation in hexadecyltrimethylammonium bromide based microemulsion. Int. J. Pharm, 1999, 184, 157-164.
96. Dalmora, M.E.; Dalmora, S.L.; Oliveira, A.G. Inclusion complex of piroxicam with-cyclodextrin and incorporation in cationic microemulsion. In vitro drug release and in vivo topical anti-inflammatory effect. Int. J. Pharm., 2001, 222, 45-55.
97. Formariz, T.P.; Urban, M.C.C.; Silva Jr., A.A.; Gremião, M.P.D.; Oliveira, A.G. Microemulsões e fases líquidas cristalinas como sistemas de liberação de fármacos. Braz. J. Pharm. Sci., 2005, 41, 301-313.
98. Heuschkel, S.; Wohlrab, J.; Neubert, R.H.H. Dermal and transdermal targeting of dihydroavenanthramide D using enhancer molecules and novel microemulsions. Eur. J. Pharm. Biopharm., 2009, 72, 552-560.
99. Moulik, S.P.; Paul, B.K. Structure, dynamics and transport properties of microemulsions. Adv. Colloid Interface., 1998, 78, 99-195.
100. Baroli, B.; Lopez-Quintela, M.A.; Delgado-Charro, M.B.; Fadda, A.M.; Blanco-Mendez, J. Microemulsions for topical delivery of 8-methoxsalen. J. Control. Release, 2000, 69, 209-218.
101. Kreilgaard, M.; Pedersen, E.J.; Jaroszewski, J.W. Characterisation and transdermal drug delivery potential of microemulsion systems. J. Control. Release, 2000, 69, 421-433.
102. López-Quintela, M.A.; Tojo, C.; Blanco, M.C.; García Rio, L.; Leis, J.R. Microemulsion dynamics and reactions in microemulsions. Curr. Opin. Colloid Interface. Sci., 2004, 9, 264-278.
103. Hathout, R.M.; Mansour, S.; Geneidi, A.S.; Mortada, N.D. Visualization, dermatopharmacokinetic analysis and monitoring the conformational effects of a microemulsion formulation in the skin stratum corneum. J. Colloid. Interface. Sci., 2011, 354, 124-130.
104. Esposito, E.; Bortolotti, F.; Menegatti, E.; Cortesi, R. Amphiphilic association systems for Amphotericin B delivery. Int. J. Pharm., 2003, 260, 249-260.
105. Bachhav, Y.G.; Patravale, V.B. Microemulsion based vaginal gel of fluconazole: formulation, in vitro and in vivo evaluation. Int. J. Pharm., 2009, 365(1-2), 175-179.
106. Hoeller, S.; Klang, V.; Valenta C. Skin-compatible lecithin drug delivery systems for fluconazole: effect of phosphatidylethanolamine and oleic acid on skin permeation. J. Pharm. Pharmacol., 2008, 60, 587-591.
107. Ellaithy, H.M.; El-Shaboury, K.M.F. The development of cutina lipogels and gel microemulsion for topical administration of fluconazole. AAPS Pharm-Sci., 2002, 3(4), 1-9.
108. Garcia-Celma, M.J.; Azemar, N.; Pes, M.A.; Solans, C. Solubilisation of antifungal drugs in water/POE(20) sorbitan monooleate/oil systems. Int. J. Pharm., 1994, 105, 77-81.
109. Muller-Goymann, C.C. Physicochemical characterization of colloidal drug delivery systems such as micelles, vesicles, liquid crystals and nanoparticles for topical administration. Eur. J. Pharm. Biopharm., 2004, 58, 343-356.
110. Namdeo, A.; Jain, N.K. Liquid crystalline pharmacogel based enhanced transdermal delivery of propranolol hydrochloride. J. Control. Release, 2002, 82, 223-236.
111. Hyde, S.T. Identification of lyotropic liquid crystalline mesophases. In: Holmberg, K., Handbook of Applied Surface and Colloid Chemistry. New York: John Wiley & Sons, 2001, vol. 16, pp.299-332.
112. Schuetze, W.; Mueller-Goymann, C.C. Mutual interactions between nonionic surfactants and gelatin-investigations in cubic liquid crystalline systems and micellar systems. Colloid Polym. Sci., 1992, 269, 85-90.
113. Gabboun, N.H.; Najib, N.M.; Ibrahim, H.G.; Assaf, S. Release of salicylic acid and diclofenac acid salts from isotropic and anisotropic nonionic surfactant systems across rat skin. Int. J. Pharm., 2001, 212, 73-80.
114. Ezrahi, S.; Aserin, A.; Garti, N. Aggregation behavior in one-phase (Winsor IV) microemulsion systems. In: Handkook of Microemulsion Science and Technology; Kumar, P.; Mittal, K.L., Ed.; Marcel Dekker: New York, 1999; Vol. 7, pp. 195-240.
115. Mannock, D.A.; Collins, M.D.; Kreichbaum, M.; Harper, P.E.; Gruner, S.M.; McElhaney. R.N. The thermotropic phase behaviour and phase structure of a homologous series of racemic beta-D-galactosyl dialkylglycerols studied by differential scanning calorimetry and X-ray diffraction. Chem. Phys. Lipids, 2007, 148(1), 26-50.
116. Guo, C.; Wang, J.; Cao, F.; Lee, R.J.; Zhai, G. Lyotropic liquid crystal systems in drug delivery. Drug Discov. Today, 2010, 15(23/24), 1032-1040.
117. Sparr, E.; Wennerström, H. Diffusion through a responding lamellar liquid crystal. A model of molecular transport across stratum corneum. Colloids Surf. B., 2000, 19, 103-116.
118. Nielsen, L.S.; Schubert, L.; Hansen, J. Bioadhesive drug delivery systems I. Characterisation of mucoadhesive properties of systems based on glyceryl mono-oleate and glyceryl mono-linoleato. Eur. J. Pharm. Sci., 1998, 6, 231-239.
119. Kelly, H.M.; Deasy, P.B.; Busquet, M.; Torrance. A.A. Bioadhesive, rheological, lubricant and other aspects of an oral gel formulation intended for the treatment of xerostomia. Int. J. Pharm., 2004, 278, 391-406.
120. Nesseem, D.I. Formulation and evaluation of itraconazole via liquid crystal for topical delivery system. J. Pharm. Biomed., 2001, 26, 387-399.
121. Höller, S.; Valenta, C. Effect of selected fluorinated drugs in a "ringing" gel on rheological behaviour and skin permeation, Eur. J. Pharm. Biopharm., 2007, 66, 120-126.